ALDX Aldeyra Therapeutics, Inc.

Nasdaq aldeyra.com


$ 4.81 $ -0.12 (-2.43 %)    

Thursday, 06-Nov-2025 15:59:58 EST
QQQ $ 613.36 $ -9.99 (-1.61 %)
DIA $ 470.23 $ -2.78 (-0.59 %)
SPY $ 671.96 $ -6.30 (-0.93 %)
TLT $ 89.61 $ 0.21 (0.23 %)
GLD $ 367.27 $ -1.11 (-0.3 %)
$ 4.81
$ 4.93
$ 4.82 x 100
$ 5.15 x 500
$ 4.80 - $ 4.95
$ 1.14 - $ 7.20
371,371
na
289.38M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-07-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 10-28-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-08-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-29-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-30-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 4-biotechnology-stocks-lead-momentum-gains-amid-strong-technicals

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

 4-biotech-stocks-seeing-explosive-momentum-gains

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...

 aldeyra-wins-ema-orphan-drug-status-for-adx-2191-to-treat-rare-eye-cancer

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan ...

 aldeyra-therapeutics-says-fda-grants-fast-track-designation-for-adx-2191-for-treatment-of-retinitis-pigmentosa

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted...

 aldeyra-resubmits-eye-drug-for-fda-review-after-new-trial-clears-key-hurdle-in-treating-dry-eye

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative th...

 hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

 aldeyra-therapeutics-to-announce-topline-results-from-phase-3-dry-eye-disease-clinical-trials-of-reproxalap-at-conference-call-scheduled-on-may-6-2025

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6...

 btig-maintains-buy-on-aldeyra-therapeutics-lowers-price-target-to-9

BTIG analyst Thomas Shrader maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from $11 to $9.

 hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION